Testosterone in men with advanced liver disease: abnormalities and implications

Area of Science:

• Endocrinology
• Hepatology
• Men's Health

Background:

• Serum testosterone reduction is prevalent in up to 90% of men with cirrhosis, worsening with disease progression.
• Low testosterone shares symptoms with advanced liver disease, including sarcopenia, osteoporosis, gynecomastia, and reduced libido.
• Testosterone deficiency in cirrhosis is increasingly linked to elevated mortality, independent of established prognostic scores.

Purpose of the Study:

• To evaluate the established role of testosterone deficiency in the symptomatology of advanced liver disease.
• To review the existing clinical evidence on testosterone therapy in men with cirrhosis.
• To establish the rationale for well-designed randomized controlled trials investigating testosterone therapy's efficacy and safety in cirrhosis.

Main Methods:

• Review of existing literature on testosterone levels in cirrhosis.
• Analysis of clinical trial data regarding testosterone therapy in cirrhosis and hypogonadism.
• Assessment of recent data on testosterone therapy risks, including hepatocellular carcinoma.

Main Results:

• Testosterone therapy in organic hypogonadism improves muscle mass, bone density, hemoglobin, and insulin resistance.
• Existing trials on testosterone therapy in cirrhosis are small and inconclusive.
• Concerns regarding testosterone therapy and hepatocellular carcinoma risk appear overstated.

Conclusions:

• A strong rationale exists for investigating testosterone therapy in cirrhosis due to its potential benefits and seemingly overstated risks.
• Further well-designed randomized controlled trials are necessary to determine the efficacy and safety of testosterone therapy in men with cirrhosis.
• Understanding testosterone's role is crucial for managing advanced liver disease symptoms and improving patient outcomes.